Hormone Therapy Linked to Arthroplasty Revision

This article originally appeared here.
Hormone Therapy Linked to Reduced Arthroplasty Revision
Hormone Therapy Linked to Reduced Arthroplasty Revision

(HealthDay News) — Hormone replacement therapy use (HRT) is associated with a reduction in revision rates for total knee arthroplasty (TKA) and total hip arthroplasty (THA), according to a study published online January 22 in the Annals of the Rheumatic Diseases.

To examine whether HRT use is associated with revision rates, Daniel Prieto-Alhambra, MD, PhD, from the University of Oxford in the United Kingdom, and colleagues identified female participants in the General Practice Research Database undergoing a primary TKA or THA from 1986–2006. Patients younger than 40 years at the date of primary arthroplasty and those with a history of previous hip fracture or rheumatoid arthritis were excluded. HRT users were defined as those using HRT for at least six months.

The researchers matched 2,700 HRT users to 8,100 nonusers, who were all observed for a median of 3.3 years after arthroplasty. For HRT use of at least six months and at least 12 months, the hazard ratios for revision were 0.62 and 0.48, respectively. Further reductions in revision rates were seen with higher adherence and therapy duration. Implant survival seemed unrelated to preoperative HRT.

"HRT use is associated with an almost 40% reduction in revision rates after a TKA/THA," the authors conclude. "These findings require replication in external cohorts and experimental studies."

The study was partially funded by grants from pharmaceutical companies.

Abstract
Full Text (subscription or payment may be required)